ISNES, Belgium, May 10, 2018 /PRNewswire/ -- VolitionRx Limited
(NYSE American: VNRX) ("Volition") today announced financial results and a business update for the first quarter ended
March 31, 2018. Volition management will host a conference call tomorrow, May 11, at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call
details may be found below.
Mr. Cameron Reynolds, President and Chief Executive Officer of Volition, said, "We have made
great progress this quarter, moving our clinical assay development strongly forward and broadening our potential revenue base
with our recently announced exclusive global license, manufacturing, sales and distribution agreement with Active Motif for a
range of research use only kits." Mr. Reynolds added, "We look forward to achieving our numerous upcoming clinical and commercial
milestones, while continuing to keep close control on our cash burn, which has remained relatively stable."
First Quarter 2018 and Recent Company Highlights
- Signed an exclusive global license, manufacturing, sales and distribution agreement with Active Motif for a range of
research use only kits.
The kits are based on our proprietary Nucleosomics® technology and are expected
to:
allow researchers to explore patterns of epigenetic modifications in circulating nucleosomes
across a broad range of clinical applications including cancers, inflammatory and infectious diseases; and
represent the first revenue from the Nu.QTM platform and potentially provide an
additional licensing revenue stream beyond the commercialization of our blood-based cancer tests on the same platform of
assays.
- We made progress on a project to investigate the use of Nucleosomics® to purify or enrich nucleosomes of tumor
origin. This project aims to provide purified ctDNA to help address the main technology barrier to ctDNA cancer
diagnostics.
- We raised $8.4 million in gross proceeds through a registered public offering of shares of
common stock.
First Quarter 2018 and Other Financial Results
Cash and cash equivalents as of March 31, 2018 totaled $14.3
million, compared with $10.1 million as of December 31,
2017.
Upcoming Milestones
We expect to achieve the following milestones during 2018 and the early part of 2019:
- Launch a range of research use only kits to be sold and distributed globally by Active Motif;
- Announce the results of the updated Nu.Q Colorectal Cancer Triage Test during the third quarter of 2018;
- Select the final panel for the Nu.Q Colorectal Cancer Frontline Screening Test based upon 4,300 samples;
- Validate the selected final panel with a 12,000-subject Colorectal Cancer Screening Cohort;
- Obtain CE marking of the updated Nu.Q Colorectal Cancer Triage Test in the fourth quarter of 2018 followed by the CE
marking of the Nu.Q Colorectal Cancer Frontline Screening Test in the first quarter of 2019;
- Release interim results on the 27 most prevalent cancers study of 4,500 subject samples, collected by the University of
Bonn, Germany, to show the breadth of the platform technology;
- Commence the Asia multi-country study in collaboration with the National Taiwan
University; and
- Obtain additional non-dilutive funding.
Mr. Reynolds concluded, "We are extremely proud of the accomplishments we have achieved thus far. I thank the dedicated
Volition team for their tireless efforts. I, along with the rest of the Board and indeed the whole company, look forward to
sharing the results of key studies and the anticipated commercialization of our platform over the coming year."
Conference Call
Volition will host a conference call tomorrow, May 11, at 8:30
a.m. U.S. Eastern Time, to discuss its financial and operating results for the first quarter of 2018, and to provide an
update on recent developments. To participate in the call, please dial 1-877-407-9716 (toll-free) in the U.S., 0-800-756-3429
(toll-free) in the U.K., and 1-201-493-6779 (toll) internationally. A live audio webcast of the conference call will also be
available via link from the investor relations page of Volition's corporate website at http://ir.volitionrx.com/. The conference ID is 13679703.
The call will be hosted by Cameron Reynolds, President and Chief Executive Officer, along with
David Vanston, Chief Financial Officer and Scott Powell, Executive
Vice President.
About Volition
Volition is a multi-national life sciences company focused on developing simple, easy to use, cost effective blood tests
designed to help diagnose a range of cancers. The tests are based on the technology platform of Nucleosomics®, which is the
practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is
present.
As cancer screening programs become more widespread, Volition's products aim to help to diagnose a range of cancers quickly,
simply, accurately and cost effectively. Early diagnosis has the potential to not only prolong the life of patients, but
also to improve their quality of life. Volition's research and development activities are currently centered in
Belgium, with additional offices in London, Texas and
Singapore, as the company focuses on bringing its diagnostic products to market first in
Europe, then in the U.S. and ultimately, worldwide.
For more information about Volition, visit Volition's website https://volitionrx.com/
or connect with us via:
Twitter: https://twitter.com/volitionrx
LinkedIn: https://www.linkedin.com/company/volitionrx
Facebook: https://www.facebook.com/VolitionRx/
YouTube: https://www.youtube.com/user/VolitionRx
The contents found at Volition's website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference
into this document and should not be considered part of this document. The addresses for Volition's website, Twitter,
LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only.
Media/Investor Contacts
Louise Day, Chief Marketing & Communications Officer
l.day@volitionrx.com
+44 (0)7557 774620
Scott Powell, Executive Vice President, Investor Relations
s.powell@volitionrx.com
+1 (646) 650 1351
Joseph Green, Edison Advisors
jgreen@edisongroup.com
+1 (646) 653 7030
Safe Harbor Statement
Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks
and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking
statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates,"
"optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify
forward-looking statements. These forward-looking statements relate to the effectiveness of Volition's bodily-fluid-based
diagnostic tests as well as Volition's ability to develop and successfully commercialize such test platforms for early detection
of cancer. Volition's actual results may differ materially from those indicated in these forward-looking statements due to
numerous risks and uncertainties. For instance, if Volition fails to develop and commercialize diagnostic products, it may be
unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory
clearances or approvals to distribute and market future products in the clinical IVD market; a failure by the marketplace to
accept the products in Volition's development pipeline or any other diagnostic products Volition might develop; Volition will
face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the
diagnostics market and its rapid technological change; and other risks identified in Volition's most recent Annual Report on Form
10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange
Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in
part, on assumptions made by management. These statements are not guarantees of future performance and involve risks,
uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release,
and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect
future events or circumstances.
Nucleosomics®, NuQ®, Nu.QTM and HyperGenomics® and their respective logos are trademarks and/or service marks of
VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release
are the property of their respective owners. Additionally, unless otherwise specified, all references to "$" refer to the legal
currency of the United States of America.
View original content:http://www.prnewswire.com/news-releases/volitionrx-limited-announces-first-quarter-2018-financial-results-and-business-update-300646342.html
SOURCE VolitionRx Ltd